Business Wire

SPLIO

Share
Splio Acquires Tinyclues to Become the European Leader in AI-powered CRM

Splio, CRM expert and developer of the SaaS Individuation® marketing platform, is proud to announce the acquisition of Tinyclues, the specialist in SaaS predictive marketing based on deep learning AI. This acquisition fulfills a shared ambition to enable brands to easily orchestrate large-scale, hyper-personalized marketing plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005122/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

On the left, David Bessis (Tinyclues) and on the right, Mireille Messine (Splio) (Photo: Splio)

Splio works with more than 400 brands, including Decathlon, Longchamp and Orange, and has been developing its own Individuation® marketing solution since 2021. Based on machine learning (AI), this solution addresses the dual challenge currently faced within CRM: how to personalize the customer experience for each individual whilst offering marketers a simple solution for large-scale orchestration.

The technological power of the Tinyclues platform increases the value proposition of Splio. A recent winner of both the Sammy and MarTech Breakthrough awards, Tinyclues is currently the most powerful predictive engine on the market, since it is the only one fueled by deep learning. It allows for the automated processing of huge volumes of first-party data for precise customer behaviour prediction. Over 100 brands use Tinyclues on a daily basis, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

The acquisition of Tinyclues thus enables Splio to establish itself as the European leader in AI-powered CRM thanks to its Individuation® marketing software, which can be rapidly and easily deployed across all industries and for companies of all sizes.

AI has become the new standard for better understanding customers and personalizing large-scale marketing communications regardless of industry or business size. Individuation® marketing based on machine learning was an initial response to these challenges. The Tinyclues platform, based on deep learning, strengthens our leadership, and provides new opportunities for sectoral and geographical growth.” Mireille Messine, CEO of Splio.

For a long time, Splio and Tinyclues have shared the same vision of CRM and the same ‘one-to-one at scale’ ambition for clients. Joining Splio enables our deep learning platform to express its full potential by allowing brands to carry out predictive marketing, including customer management and activation.” David Bessis, CEO of Tinyclues.

As a result of this acquisition, Splio now has 250 employees in Europe and the MEA and a portfolio of 500 business clients, from medium-sized companies to large groups from a large range of industries (retail, restaurant, telecoms, travel, hotel, leisure, etc.) with an annual recurring revenue over €30m.

About Splio

Splio is a Martech company headquartered in Paris, with 200 employees, 90 of whom work in Product and R&D, and five offices in Europe and the MEA.

Splio provides a SaaS Individuation® marketing platform to B2C customer marketing professionals. The company has a portfolio of more than 400 brands, from medium-sized enterprises to major groups from four key industries (retail, e-commerce, restaurant and telecom), including Longchamp, Decathlon, Rue du Commerce, Nicolas, Brioche Dorée and Orange.

Splio aims to empower marketing automation with Individuation® enabling companies to activate and engage each of their customers on a case-by-case basis in a unique relationship using AI.

The Individuation® marketing platform is based on a one-of-a-kind innovation that automates each day the most relevant communications to the most appropriate channels for each one of a companies’ customers. The platform is uniquely capable of calculating the optimum based both on a company’s objectives and on the appetencies of each of its customers.

Mireille Messine is the CEO of Splio and Gregory Chapron the Co-CEO. Investors include Sofiouest, Ring Capital, BPI-FAN, Omnes, Seventure, Amundi PEF, BNP Paribas Développement and SWEN.

About Tinyclues

Tinyclues is a Martech company whose precision-AI targets individuals based on buying propensity. Over 100 brands currently use the solution, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.

Tinyclues’ cutting-edge technology analyses often-ignored first-party data signals so that CRM teams can accurately predict customer purchase intent and easily orchestrate complex marketing plans.

Tinyclues was the winner of the Sammy Award for Product of the Year in 2021 and the Martech Breakthrough Award for Best CRM Solution for Enterprises in 2021 and 2022. Tinyclues has been listed as a ‘Vendor to Watch’ in Gartner’s Magic Quadrant for Digital Marketing Analytics and as a ‘Cool Vendor’ within its Multichannel Marketing Report. In addition, G2 awarded Tinyclues the ‘Users Love Us’ and ‘High Performer’ certificates in 2021 and 2022.

Tinyclues’ investors include ISAI, Elaia, Alven Capital and EQT Ventures.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005122/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons to acquire AOL following $2.8B debt financing29.10.2025 16:30:00 CET | Press release

Acquisition positions historic brand for its next phase of growth Technology company Bending Spoons today announced that it has entered into a definitive agreement to acquire AOL, the web portal and email provider, from Yahoo. The acquisition is expected to close by the end of the year, subject to customary closing conditions and regulatory approvals. “AOL is an iconic, beloved business that’s in good health, has stood the test of time, and we believe has unexpressed potential,” said Bending Spoons CEO and co-founder, Luca Ferrari. “By our estimation, AOL is one of the top ten most-used email providers in the world, with a highly retained customer base counting around 8 million daily and 30 million monthly active users. We intend to invest significantly to help the product and the business flourish. Bending Spoons has never sold an acquired business—we’re confident we’re the right long-term steward for AOL, and look forward to serving its large, loyal customer base for many years to co

Doha Debates Questions Whether Modern Architecture Contributes to Cultural Decline29.10.2025 16:15:00 CET | Press release

Episode two of flagship debate show asks: Have we lost touch with beauty in the world we have built? This week, Qatar Foundation’s Doha Debates examines how architecture reflects and shapes cultural values on their flagship show, Doha Debates. The second episode of the new season asks: Has modern architecture redefined beauty and tradition, or contributed to its decline? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029822479/en/ Doha Debates brought together a distinguished group of architects, thinkers, and creatives to question whether modern architecture contributes to cultural decline. From left: Sundus Saeed, Ameer Sadi, Sara Akbar, Carl Jambo, Huda Muazzam Iqbal, Tariq Khayyat, Bidisha Sinha, Dareen Abughaida, Carl W. Korsnes, Marwa Al-Sabouni, Leen Nedal Yamin, Wahed Shaik, Lina Ayman Darwish, Mudassar Raza Shakir, and John Carlos Burog. (Photo: AETOSWire) Moderated by Dareen Abughaida, the debate brings students

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities29.10.2025 15:35:00 CET | Press release

Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/ Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol

Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 14:30:00 CET | Press release

Positioning Recognises Phenom Applied AI Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategi

Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®29.10.2025 14:00:00 CET | Press release

As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye